Brigatinib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Brigatinib. Educational only — not medical advice.
Labeled uses
ALUNBRIG is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test [see Dosage and Administration (2.1) ] .
Source: FDA labeling via NIH DailyMed (set 0fe9ff20…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.